The European Commission has approved lower-dose capsules of Roche Holding AG's flu treatment Tamiflu, allowing the drug giant to sell 30 mg and 45 mg doses of the drug for children ages 1 and older. The smaller doses have a longer shelf life than the formulation currently used for children that benefits government pandemic stockpiling, Roche said.

Related Summaries